Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Equillium, Inc. - Common Stock (NQ:EQ)

0.4910 -0.0128 (-2.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
From Equillium, Inc.
Via Business Wire
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
From Equillium, Inc.
Via Business Wire
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
From Equillium, Inc.
Via Business Wire
Equillium's Itolizumab Shows Durable Clinical Response In GvHD Patients
Equillium Inc (NASDAQ: EQ) announced two oral presentations on itolizumab at the Annual Meeting of the European Society for Blood and Marrow Transplantation.  
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to... 
Via Benzinga
Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition
Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. The deal,... 
Via Benzinga
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
From Equillium, Inc.
Via Business Wire
Equillium Provides Timing Update on Conference Presentations
From Equillium, Inc.
Via Business Wire
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Mustang Bio (NASDAQ:MBIO) shares ... 
Via Benzinga
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
From Equillium, Inc.
Via Business Wire
10 Biggest Price Target Changes For Wednesday
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on... 
Via Benzinga
45 Biggest Movers From Yesterday
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced... 
Via Benzinga
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Equillium To Reassess Potential For Its Asthma Trials
Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target... 
Via Benzinga
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
From Equillium, Inc.
Via Business Wire
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
From Equillium, Inc.
Via Business Wire
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
From Equillium, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.